18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
Trial Parameters
Brief Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility Criteria
Inclusion Criteria: 1. Aged 30-80 years old, primary school or above, with a regular caregiver; 2. Clinically diagnosed patients with pheochromocytoma; 3. Can provide informed consent, can understand and comply with the study requirements. Exclusion Criteria: 1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg); 3. Patients with mental disorders or primary affective disorders; 4. Unable to understand and adhere to the study protocol or provide informed consent; 5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.); 6. Allergy to imaging agents; 7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.